Moderna, Inc. (MRNA) Financials
Annual revenue, profitability and per-share results for Moderna, Inc., as reported in SEC filings.
Revenue · FY2025
$1.94B
▼ 39.9%YoY
Net income · FY2025
-$2.82B
▲ 20.8%YoY
Diluted EPS · FY2025
$-7.26
▲ 21.8%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $1.94B | -$2.82B | — | $-7.26 | -$2.06B | -158.1% | -39.9% |
| FY2024 | $3.24B | -$3.56B | — | $-9.28 | -$4.05B | -121.9% | -52.8% |
| FY2023 | $6.85B | -$4.71B | — | $-12.33 | -$3.83B | -61.9% | -64.5% |
| FY2022 | $19.26B | $8.36B | — | $20.12 | $4.58B | 48.9% | +4.3% |
Figures as reported in Moderna, Inc.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a MRNA filing.
Get an email when MRNA files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.